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a  b  s  t  r  a  c  t
The  discovery  that the  bacterial  clustered  regularly  interspaced  short  palindromic  repeats
(CRISPR)–CRISPR-associated  protein  9 (Cas9)  acquired  immune  system  can  be  utilized  to create  double-
strand  breaks  (DSBs)  in eukaryotic  genomes  has  resulted  in  the  ability  to  create  genomic  changes  more
easily  than with  other  genome  engineering  techniques.  While  there  is  signiﬁcant  potential  for  the
CRISPR–Cas9  system  to advance  basic  and  applied  research,  several  unknowns  remain,  including  the
speciﬁcity  of the RNA-directed  DNA  cleavage  by the small  targeting  RNA,  the  CRISPR  RNA  (crRNA).  Here
we describe  a novel  synthetic  RNA  approach  that  allows  for high-throughput  gene  editing  experiments.
This  was  used  with  a  functional  assay  for protein  disruption  to  perform  high-throughput  analysis  of
crRNA  activity  and  speciﬁcity.  We  performed  a comprehensive  test  of target  cleavage  using  crRNAs  thatenome engineering
unctional assay
rRNA
contain  one  and  two  nucleotide  mismatches  to the  DNA  target  in  the  20mer  targeting  region  of  the  crRNA,
allowing  for  the  evaluation  of  hundreds  of potential  mismatched  target  sites  without  the  requirement  for
the off-target  sequences  and  their  adjacent  PAMs  to be present  in  the  genome.  Our  results  demonstrate
that  while  many  crRNAs  are functional,  less  than  5% of  crRNAs  with  two  mismatches  to  their  target  are
effective  in  gene  editing;  this  suggests  an  overall  high  level  of  functionality  but low  level  of  off-targeting.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
The CRISPR–Cas9 system is a highly effective and simple tech-
ique for modifying the genome of higher eukaryotes, particularly
ammalian cells that have not been readily amenable to gene
diting. In the short period since the initial discovery of efﬁ-
acy in mammalian cells (Cong et al., 2013; Mali et al., 2013;
inek et al., 2013; Cho et al., 2013), there have been numerous
tudies that demonstrate the utility of the CRISPR–Cas9 system
Abbreviations: CRISPR, clustered regularly interspaced palindromic repeats;
as9, CRISPR associated protein 9; crRNA, CRISPR RNA; tracrRNA, trans-activating
RISPR RNA; PAM, protospacer adjacent motif; sgRNA, single guide RNA; NGS, next
eneration sequencing; PSC, pluripotent stem cells; ACE, monoacetate orthoester;
iRNA, small interfering RNA; T7E1, T7 endonuclease I; PCR, polymerase chain reac-
ion; GFP, green ﬂuorescent protein; EGFP, enhanced green ﬂuorescent protein;
bi-GFP, ubiquitin-conjugated green ﬂuorescent protein; DNA, deoxyribonucleic
cid; RNA, ribonucleic acid; GUIDESeq, genome-wide unbiased identiﬁcations of
SBs evaluated by sequencing; DSB, double-strand break.
∗ Corresponding author.
E-mail address: anja.smith@ge.com (A.v.B. Smith).
ttp://dx.doi.org/10.1016/j.jbiotec.2015.06.427
168-1656/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
for genome engineering, from performing whole-genome-scale
knockout screens elucidating gene function in cell culture (Shalem
et al., 2014; Wang et al., 2014), to creating multiple mutations mod-
eling tumors in the livers and lungs of adult mice (Xue et al., 2014;
Platt et al., 2014) and creating mutations in the brains of adult mice
(Swiech et al., 2015). This CRISPR system requires the Cas9 nucle-
ase along with two  short RNA molecules, the guiding CRISPR RNA
(crRNA) and the trans-activating crRNA (tracrRNA), that hybridize
to each other and direct Cas9 to the target location for cleavage
based on sequence complementarity to the crRNA as well as prox-
imity of the DNA target to a protospacer adjacent motif (PAM). In
2012, Jinek et al. (2012) demonstrated that the two small RNAs,
crRNA and tracrRNA, can be combined into a single guide RNA
(sgRNA) that can be expressed in mammalian cells. While the effec-
tiveness and universality of CRISPR–Cas9 for genome engineering
in mammalian systems has been clearly demonstrated, the activity
and speciﬁcity of a particular crRNA or chimeric sgRNA is less clear.The ability of any given crRNA to efﬁciently create a DSB in the
target DNA can vary based on the guide RNA (gRNA; either crRNA
or sgRNA) sequence and position in the targeted gene (Shalem
et al., 2014; Wang et al., 2014; Koike-Yusa et al., 2014). A recent
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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tudy has identiﬁed sgRNA design rules that predict functional
gRNAs (Doench et al., 2014). Likewise, several publications have
emonstrated variable levels of off-target cleavage for speciﬁc
gRNAs (Cong et al., 2013; Cho et al., 2014; Fu et al., 2013; Lin
t al., 2014; Pattanayak et al., 2013; Hsu et al., 2013). For exam-
le, Fu et al. (2013) examined the activity of sgRNAs that contained
ingle, double, and multiple mismatches with the target DNA.
heir results demonstrated that, in general, single mismatches are
ell-tolerated at the 5′ end of the sgRNA, adjacent double mis-
atches can still result in cleavage for some sequences, and three
r more adjacent mismatches at the 5′ end of the sgRNA elim-
nate activity. When testing potential off-target sites that were
redicted bioinformatically, CRISPR–Cas9-dependent cleavage was
nly detected at a small subset of these endogenous potential
ff-target sites. In addition, off-targeting was demonstrated using
equences containing up to ﬁve nonadjacent mismatches to their
arget, suggesting that sequences with more mismatches to a
otential off-target do not necessarily yield reduced off-targeting.
ff-target sites including DNA or RNA bulges at certain positions
elative to the sgRNA strand have also been shown to be cleaved
y CRISPR–Cas9 (Lin et al., 2014). These results show context and
equence dependencies including a correlation with GC content.
n contrast, whole-genome next-generation sequencing (NGS) of
uman pluripotent stem cell (PSC) clones or induced PSC clones
argeted with CRISPR–Cas9 showed very few to no off-target muta-
ions that could be attributed to CRISPR–Cas9 (Smith et al., 2014;
eres et al., 2014). In these studies, clonal artifacts derived from
solating CRISPR–Cas9-edited cells appeared to be a larger con-
ern, suggesting that off-targeting is not a signiﬁcant issue for
sing CRISPR–Cas9 in human PSCs. The rules governing which mis-
atches between the crRNA and target DNA are tolerated and
herefore result in off-target effects remain unclear.
In consideration of the variety of reports outlined above, we
erformed a comprehensive evaluation of off-target potential of
rRNAs containing mismatches with the target DNA. While Fu
t al. evaluated transversion mutations at all possible single mis-
atches throughout 19 of the 20 nucleotides, their evaluation of
ouble mismatches was limited to adjacent mismatches and a sub-
et of variably spaced ones. Likewise, Hsu et al. evaluated varying
ombinations of mismatches, both interspersed and concatenated,
ut they did not assess all possible mismatch combinations, likely
ue to the technical infeasibility of generating and assaying large
umbers of sgRNA designs. Here, we exploit a functional assay
aired with synthetic crRNAs to assess the effects of mismatches
n a high-throughput manner, including a comprehensive analysis
f all possible crRNA positions containing two mismatches. This
pproach allows for a systematic and thorough investigation of
ositional preferences in off-targeting, since a very large number
f combinations can be tested without prior knowledge of whether
he off-target sites occur endogenously in the genome alongside a
AM. In a genomewide study design, for instance utilizing NGS, a
uch larger set of crRNAs would have to be assayed to represent
very position in the crRNA targeting sequences with the assurance
hat all or a large number of the potential off-target sequences were
epresented in silico.
. Materials and methods
.1. Generating a stable cell line expressing Cas9.1.1. Cas9 lentiviral particle production
A lentiviral vector containing a human codon-optimized Strepto-
occus pyogenes Cas9 gene under control of the hCMV promoter and
 puromycin resistance gene was packaged into lentiviral particlesechnology 211 (2015) 56–65 57
using the Trans-Lentiviral Packaging Kit (Dharmacon, #TLP5919)
(Kappes and Wu,  2001; Kappes et al., 2003).
2.1.2. Creation of Cas9 stable cell lines
Recombinant U2OS cells that stably express a mutant human
ubiquitin fused to EGFP (Thermo Scientiﬁc BioImage Proteasome
Redistribution Assay, #R0402102) were seeded at 100,000 cells
per well in a 24-well plate (Costar, #3524). The following day,
cells were transduced with 3 L of Cas9 lentiviral particles (rough
estimate of viral titer: 1 × 106 viral particles per mL). The cells
were expanded into a 6-well plate (Thermo Scientiﬁc, #140675)
72 h post-transduction. After a 48-hour recovery and expansion
period, the cells were exposed to 2 g/mL of puromycin (Invivo-
gen, #ant-pr-5). Cells that survived the selection were harvested
and utilized in the following experiments and are referred to as
Ubi-GFP U2OS–Cas9.
2.2. Design of crRNA and tracrRNA
Full-length crRNAs were designed by appending the S. pyogenes
crRNA repeat sequence, 5′ GUUUUAGAGCUAUGCUGUUUUG 3′, to
each target sequence.
crRNAs were designed to target VCP, PPIB, MYBB1, DNMT3B,
CDKNIA, VEGFA and EMX1 (Supplementary Table 1). VEGFA and
EMX1 crRNA sequences were obtained from Fu et al. (2013). For
saturation studies, 266 crRNAs to most positions across the VCP
were designed (Supplementary Table 2).
For speciﬁcity studies, two  functional target sequences were
selected (VCP 2: 5′ UCAUCAACAAUUAACCGAUU 3′ and PSMD7 1:
5′ AGCGGGGUGUGUCGCGAUGC 3′). For each one, a set of alternate
sequences with disruptive 2-base mismatches across the ﬁrst 20
targeting nucleotides was designed by replacement of each base
with its Watson–Crick partner (A–U, U–A, G–C, and C–G) at two
separate positions in all possible combinations of positions. This
resulted in 190 2-base mismatch sequences for each of the two
crRNAs (Supplementary Table 3).
The tracrRNA is a 74-nucleotide RNA (5′
AACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACU-
UGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU 3′) based on the
published S. pyogenes tracrRNA sequence (Jinek et al., 2012).
2.3. Synthesis of crRNA and tracrRNA
All crRNAs and tracrRNA were chemically synthesized on
solid-phase support using 5′-silyl-2′-orthoester (ACE) chemistry
(Scaringe, 2001; Wincott et al., 1995). crRNAs were deprotected,
desalted, and used without further puriﬁcation. The tracrRNA was
additionally HPLC-puriﬁed.
2.4. Transfections
HEK293T, Ubi-GFP U2OS–Cas9, U2OS and ESD3 cells were
seeded in a 96-well plate in a density appropriate for each spe-
ciﬁc assay. The following day crRNA and tracrRNA were individually
resuspended in 10 mM Tris–HCl (pH7.5), 100 mM NaC, and 1 mM
EDTA. 100 M crRNA and tracrRNA were added together and the
RNA was  further diluted to 5 M using sterile 1X siRNA Buffer
(Dharmacon, B-002000-UB-100). A ﬁnal concentration of 50 nM
crRNA:tracrRNA (50 nM of each crRNA and tracrRNA) was used
for transfection. The cells were transfected with DharmaFECT Duo
Transfection Reagent (Dharmacon, # T-2010-03) using 100 ng of
Cas9 plasmid (for co-transfections) and 50 nM crRNA:tracrRNA
complex.
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.5. Genomic DNA isolation and mismatch-detection assay
Genomic DNA was isolated 72 h post-transfection by direct lysis
f the cells in Phusion HF buffer (Thermo Scientiﬁc, #F-518L), pro-
einase K and RNase A for 1 h at 56 ◦C followed by heat inactivation
t 96 ◦C for 5 min. PCR was  performed with primers ﬂanking the
leavage sites (Supplementary Table 4). 500 ng of PCR products was
reated with T7 endonuclease I (T7EI; NEB, #M0302L) for 25 min  at
7 ◦C and the samples were separated on a 2% agarose gel. Percent
diting in each sample was calculated using ImageJ.
.6. Sanger sequencing
Blunt-end PCR products generated for the mismatch-detection
ssay were cloned into pCR-Blunt using the Zero Blunt PCR Cloning
it according to the manufacturer’s protocol (Life Technologies,
K2700-20). Transformed colonies were picked into 96-well plates
nd grown overnight in NZYM PLUS broth (Teknova, #N1220)
nd 8% glycerol. Frozen 96-well plates were sent to Oblique Bio,
nc. (Huntsville, AL) for mini-prep and Sanger sequencing. Chro-
atograms were analyzed with Geneious Version 6.1.8, created by
iomatters (www.geneious.com).
.7. Functional screening of gene editing
.7.1. Proteasome assay
Ubi-GFP U2OS–Cas9 cells were plated at 3500 cells per well in
ostar Black 96-well tissue culture treated plates (Costar, #3916)
n DMEM high glucose supplemented with 10% fetal bovine serum.
ells were incubated at 37 ◦C, 5% CO2 for 24 h before transfection.
ells were transfected in triplicate using 0.08 L/well Dharma-
ECT #3 (Dharmacon, T-2003-01) diluted in reduced serum media
HyClone, SH30564.01). Cells were returned to the 37 ◦C, 5% CO2
ncubator for 72 h prior to analysis.
.7.2. ArrayScan detection
Cells were washed with 1X DPBS and treated with 4%
araformaldehyde for 30 min. Cells were then washed two  times
ith 1X DPBS and Hoechst stained for 5 min. Plates were analyzed
n the Cellomics ArrayScan VTI HCS Reader (Thermo Scientiﬁc)
t 5 × magniﬁcation, using a target activation method in the Cel-
omicsScan Software (Thermo Scientiﬁc), where GFP-positive cells
re identiﬁed as selected cells. A total of nine ﬁelds of view at 5×
ere imaged per well. Total number of cells and percent selected
ells were reported and used for analysis. Individual images were
nalyzed for artifacts that could be erroneously calculated as GFP-
ositive cells by the analysis software; any wells containing these
rtifacts were discarded from the data set.
.7.3. Data analysis
Percent selected (GFP positive) cells per well for each bio-
ogical triplicate were normalized to average of percent selected
ells for the positive control (perfect match sequence) on
ach plate. Average normalized percent GFP positive cells and
tandard deviation for each biological triplicate is reported.
obust z-score (x − median(sample)/MAD(sample) × 1.4826 where
 = sample value and MAD  is the median absolute deviation of the
on-control samples) was also calculated. Any 2-base-mismatched
rRNA to the targets VCP 2 or PSMD7 1 with a robust z-score of
100 was selected as a hit; this score threshold was  chosen as it
dentiﬁes all positive controls and no negative controls.echnology 211 (2015) 56–65
3. Results
3.1. Efﬁcient gene editing using Cas9 and synthetic crRNA and
tracrRNA
Most published studies using CRISPR–Cas9 for gene editing have
used a sgRNA cloned into and expressed from a plasmid to direct
target cleavage. A wide range of gene editing efﬁciencies have been
reported (<1–>50%), depending on the sgRNA and the target. While
the use of a sgRNA is convenient for expression from a plasmid, this
approach requires cloning and sequence veriﬁcation of every con-
struct; this approach is not amenable to high-throughput screening
of crRNA sequences. We  referred back to the original bacterial
Type II CRISPR system and used a two-RNA approach, combining
expression of the Cas9 protein with delivery of two  synthetic RNA
molecules endogenous to the bacterial CRISPR–Cas9 system: the
processed (or mature) 42-mer crRNA and the 74-mer tracrRNA
(nucleotides 15–89 of the primary transcript, derived from Sup-
plementary Table 1 of Jinek et al. (2012)) (Fig. 1A). We synthesized
these two RNA molecules using 2′ACE RNA chemistry, resulting in
high yield and purity of full-length RNA.
We tested the efﬁciency of genome editing using synthetic
crRNA and tracrRNA molecules on several gene targets, including
those that have been published using sgRNAs. A mismatch-
detection assay (for example, SURVEYOR or T7EI; Fig. 1B–E) is
typically used for the detection and quantiﬁcation of insertions
and deletions (indel) mutations created by the CRISPR–Cas9 sys-
tem (Vouillot et al., 2015). As shown in Fig. 1B, co-transfection of a
plasmid expressing Cas9 in combination with synthetic crRNA and
tracrRNA results in indels at the targeted site. The dual synthetic
RNA approach is also effective in multiple cell lines (Supplemen-
tary Fig. 1A,B). To evaluate the off-target proﬁle of Cas9 targeting
using synthetic crRNAs and tracrRNA, we  designed and synthesized
crRNA molecules to three sequences in the human genome (two
sites in VEGFA and one site in EMX1) that have previously been
shown by a mismatch-detection assay to result not only in effec-
tive target cleavage but also in off-target editing at other sites in
the genome (Fu et al., 2013). We  detected off-target editing at the
same locations reported for sgRNAs (Fig. 1C–E, Supplementary Fig,
2), and the efﬁciency of these events was consistent with efﬁcien-
cies reported for sgRNAs (Mali et al., 2013), as detected by the T7EI
mismatch-detection assay. These data demonstrate that the use of
synthetic crRNA and tracrRNA molecules results in a similar pat-
tern of on- and off-targeting in mammalian cells when compared
to expressed sgRNAs.
3.2. Evaluation of a functional reporter assay to assess gene
editing in a high-throughput manner
Because the sequence of the tracrRNA is constant regardless
of the crRNA sequence, hundreds or even thousands of different
crRNA targeting sequences can be evaluated in a high-throughput
manner simply by synthesizing the 42-mer crRNA sequence and
co-transfecting it with tracrRNA. We  applied this approach to
design a high-throughput assay which evaluates CRISPR–Cas9-
mediated on- and off-targeting in mammalian cells. Although
mismatch-detection assays (Fig. 1B–E) are fairly straight-forward,
they are time-consuming, require identiﬁcation and validation of
PCR primers for each target site, and are not suitable for high-
throughput screening of crRNAs. We therefore validated a reporter
cell line stably expressing EGFP fused to a non-cleavable mutant
ubiquitin moiety as a functional readout of CRISPR–Cas9 gene edit-
ing (Dantuma et al., 2000). These Ubi-GFP U2OS cells constitutively
degrade the EGFP fusion through the proteasome pathway, result-
ing in little to no GFP ﬂuorescence. However, if the proteasome
complex or pathway is compromised or disrupted, the EGFP fusion
E.M. Anderson et al. / Journal of Biotechnology 211 (2015) 56–65 59
Fig. 1. CRISPR–Cas9-mediated gene editing using synthetic crRNAs and tracrRNA. (A) Diagram showing genome engineering using the CRISPR–Cas9 system consisting of the
synthetic crRNA and tracrRNA. (B) Co-transfection of a plasmid expressing a humanized Cas9 and synthetic crRNA and synthetic tracrRNA results in targeted DNA cleavage
in  HEK293T cells. Cells were transfected with Cas9 plasmid, synthetic crRNA, and synthetic tracrRNA, and compared to untransfected cells (UT) using the T7 endonuclease
I  (T7EI) assay. The percent editing after 72 h is indicated at the bottom of each lane. (C–E) Transfections were performed as in (B) and off-target gene editing with synthetic
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trRNA  and tracrRNA was determined for VEGFA (C–D) and EMX1 (E) as previously 
resent  in untransfected samples and were not included in the indel quantiﬁcation
o  the web version of this article.).
s no longer constitutively degraded and cells begin to accumulate
bi-GFP.
We additionally stably integrated the Cas9 gene into this
eporter cell line and performed CRISPR–Cas9 gene editing by
ransfecting synthetic crRNAs and tracrRNA targeting known com-
onents of the proteasome that we had previously validated using
iRNAs (data not shown). As seen in Fig. 2A, crRNAs targeting
CP and PSMD7 resulted in detectable levels of EGFP, indicating
hat proteasome function had been disrupted in these cells, while
here was no increase in EGFP ﬂuorescence in untreated cells.ted with sgRNA (Fu et al., 2013). Red asterisks indicate non-speciﬁc bands that are
nterpretation of the references to color in this ﬁgure legend, the reader is referred
The transfections were performed at a saturating concentration
of 50 nM crRNA and tracrRNA to ensure maximal editing activ-
ity. The sensitivity of this reporter assay is high due to the very
low levels of background in untreated cells (0–5 cells, where in an
average well approximately 7700 cells are analyzed; 0.06%); we
can therefore conﬁdently detect positive functional activity with
statistical signiﬁcance down to 10% or less activity of the perfectly-
matched crRNA. For instance, for a perfectly-matched target, 1500
cells are functionally disrupted in proteasome activity and there-
fore are EGFP-positive (22%). While 6 cells can theoretically be
60 E.M. Anderson et al. / Journal of Biotechnology 211 (2015) 56–65
Fig. 2. Gene editing in Ubi-GFP U2OS–Cas9 cells. (A) Ubi-GFP U2OS–Cas9 cells were transfected with synthetic crRNAs and tracrRNA targeting two  genes involved in
proteasome function, VCP and PSMD7 (using the VCP 2 crRNA or the PSMD7 1 crRNA), or were left untreated. GFP phenotype was assessed by high-content imaging 72 h post-
transfection, and representative images are shown. The percent GFP-positive cells was  quantiﬁed by calculating average values from biological triplicates: VCP = 10.3 ± 1.2%,
PSMD7 = 10.6 ± 0.5%, Untreated = 0.0 ± 0.0%. (B) Assessment of gene editing using the T7EI mismatch-detection assay in untreated (−) or cells treated with the indicated
c low e
f
d
t
1
t
trRNA  and tracrRNA (+). The percent gene editing for treated samples is indicated be
rom  untreated (UT) or cells treated with the indicated crRNA and tracrRNA.
etected above background (0.08%), we conservatively picked a sta-
istical threshold for signiﬁcance corresponding to approximately
50 cells per well (∼2%), resulting from a Robust z-score calcula-
ion, as described in Section 2. We  also evaluated treated cells for
he presence of indels using the T7EI assay (Fig. 2B). We  consis-ach lane. (C) Summary of results from sequencing individually cloned PCR products
tently observed that the indel mutation percentages seen using a
mismatch-detection assay are higher in the Ubi-GFP U2OS–Cas9
cell line than those seen in co-transfection experiments (Supple-
mentary Fig. 1A compared to Fig. 2B); possible explanations for this
discrepancy include transfection efﬁciency of the Cas9-expressing
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lasmid or levels of Cas9 protein required for efﬁcient gene edit-
ng. To further analyze the indels in the PSMD7 and VCP genes after
ransfection with PSMD7- and VCP-targeting crRNAs (PSMD7 1 and
CP 2, respectively), we cloned the PCR products containing the
arget sites from transfected cell populations into Escherichia coli
nd sequenced individual colonies. As shown in Fig. 2C and Sup-
lementary Table 5, sequencing results showed a variety of indels
round the crRNA target site. To rigorously control for detection
f indels by sequencing, untransfected cells were sequenced at the
diting target site to detect the background levels of indels that
re likely due to inherent errors in the PCR, sequencing method
nd possibly mutations in the population. As expected, the fre-
uency of mutations in the treated population was signiﬁcantly
igher than untransfected background and consistent with the
requency determined by T7EI. This background level is not due
o Cas9 expression alone in this cell line and is consistent with
eported error rates of PCR and Sanger sequencing (Ewing et al.,
998). The EGFP ﬂuorescence results (Fig. 2A) show lower levels
f gene editing than the sequencing results (Fig. 2C), but can be
xplained by the fact that the EGFP ﬂuorescence detected in this
ssay will only reﬂect indels that result in functional disruption of
he target protein and is therefore likely to be an underestimate
f the total number of indels. In addition, functional disruptions
ill require disruptive indels in all (or most) alleles of the gene;
hus, in U2OS cells that are known to be polyploid (Janssen and
edema, 2013), indels may  occur at one or more alleles but not
e sufﬁcient to disrupt the proteasome to the extent that results in
he GFP-positive phenotype in this assay. Nonetheless, signiﬁcant
evels of functional mutations are detected in this assay using the
RISPR–Cas9 system, conﬁrming that the Ubi-GFP U2OS–Cas9 cell
ine can be used as a high-throughput assay for determining crRNA
unctionality. We  used the assay to test 266 crRNAs (each proximal
o an NGG PAM) across all coding exons of the VCP gene. Our results
ndicate that many crRNAs (244 of 266 or 92%) exhibit some level of
unctionality, as deﬁned by >1.1-fold increase in GFP ﬂuorescence,
r disruption of proteasome function leading to the stability and
etection of Ubi-GFP (Supplementary Table 2 and Supplementary
ig. 3), highlighting the fact that ﬁltering of crRNAs based on speci-
city predictions will likely still allow for many functional crRNAs
o a given gene.
.3. Functionality of crRNAs containing single, double, or triple
ismatches to the intended targets
To evaluate the potential of crRNAs to target and cleave off-
arget sequences with imperfect complementarity, we synthesized
rRNAs with mismatches to the VCP and PSMD7 genes as a proxy for
ff-targeting in the Ubi-GFP U2OS–Cas9 cell line. First we synthe-
ized crRNAs containing a single disruptive transversion mismatch
o the DNA target (A to U, C to G, U to A, G to C) throughout the
0-nucleotide length of the crRNA targeting VCP (VCP 2 crRNA) or
SMD7 (PSMD7 1 crRNA) (Supplementary Table 3). Transversion
ismatches were selected to narrow down the possible sequence
pace from a mismatch matrix that rapidly becomes intractable
hen considering combinations of two or more mismatches, while
till sampling comprehensively across every position of the target-
ng region of the crRNA. As previously described (Cho et al., 2014; Fu
t al., 2013; Hsu et al., 2013) using both a reporter mismatch assay
nd a sampling of predicted endogenous off-targets (Fu et al., 2013),
ingle-base mismatches are tolerated (resulting in detectable and
igniﬁcant mismatch targeting relative to the on-target activity),
articularly if the mismatches occur in the PAM-distal end of the
rRNA, away from the seed region, deﬁned here as nucleotides 1–10
f the crRNA (Fig. 3A).
We then synthesized crRNAs with all possible combinations of
wo-nucleotide disruptive mismatches to the DNA target for theechnology 211 (2015) 56–65 61
VCP 2 crRNA and the PSMD7 1 crRNA, yielding 190 mismatch-
containing crRNAs per gene (Supplementary Table 3). We  evaluated
the ability of these 380 crRNAs containing two mismatches to their
targets to create indels in their respective gene (thereby resulting in
EGFP ﬂuorescence), despite having imperfect complementarity to
the target. As shown in Fig. 3B and C (light blue data points in inset
graphs), fewer than 5% of the crRNA sequences that contain two
disruptive mismatches to their target are able to effectively cleave
and create mutations in their target, as detected by EGFP ﬂuores-
cence. For the crRNA targeting VCP (VCP 2), only 7 of the 190 crRNAs
(3.7%) with two  mismatches remain able to target the VCP gene as
assessed by a statistical cut-off of robust z score > 100 (Fig. 3B and
Table 1), which is roughly 10% relative activity compared to the
on-target effect. As described earlier, a few mismatched sequences
exhibited signal in this assay even below this threshold, but they
would not be robustly reproducible enough to produce a func-
tional effect. Therefore we  deem them statistically insigniﬁcant
in terms of representing what might truly be detected in a cell
population as proxy for an endogenous off-target effect. For the
crRNA targeting PSMD7 (PSMD7 1), only 8 of the 190 crRNAs (4.2%)
with two  mismatches remain able to target the PSMD7 gene using
the same statistic (Fig. 3C and Table 1). Using T7EI, we conﬁrmed
that the 15 mismatch-containing crRNAs targeting VCP and PSMD7
resulting in EGFP ﬂuorescence do indeed trigger indel formation
and for these functional target sites, the percent editing from the
mismatch-detection assay correlates with the magnitude of pheno-
typic readout (Fig. 4A and B). Of the 15 sequences that are able to
cleave the target DNA site despite the presence of two mismatches,
11 of these contain a mismatch at position 1, or the most PAM-distal
position. This result is consistent with previous data demonstrat-
ing that the identity of position 1 is not important for effective gene
editing; indeed, many studies using expressed sgRNAs replace posi-
tion 1 with a G, which is a requirement of the U6 promoter driving
sgRNA expression (Cong et al., 2013; Koike-Yusa et al., 2014; Fu
et al., 2013). Our results show that both positions 1 and 2 are tol-
erant of mismatches between the RNA and target DNA for both
crRNAs that we tested, suggesting that mismatch tolerance may
extend beyond position 1. Consistent with the single-mismatch
data (Fig. 3A), those mismatches closer to the seed region (at posi-
tions 9, 10 and 13 from the 5′ PAM-distal end) are also tolerated in
spite of this proximity.
For every crRNA, there are 1140 possible sequences containing
three mismatches to the target sequence, even if only disruptive
transversion mismatches as described above are considered. Given
that most of the two-mismatch sequences tested did not result in
off-targeting and the three mismatch set is large, we  chose to evalu-
ate only a subset of three-mismatch sequences that we anticipated
were the most likely to off-target, rather than the entire set (Sup-
plementary Table 3). Two approaches for choosing three-mismatch
sequences were used: ﬁrst, to those two-mismatch sequences that
resulted in the most off-targeting, as shown above, we  added a
disruptive mismatch at each remaining position of the targeting
20-mer. Second, positions in the two-mismatch study that showed
any off-targeting were combined and tested as three-mismatch
combinations. We  found that most of the three-mismatch crRNA
sequences showed no functional targeting (Fig. 3D, Supplemen-
tary Fig. 4) with the exception of the sequence with mismatches
at positions 1, 2, and 3 of the PSMD7 1 crRNA, which was able
to target at low levels. This result is consistent with the single-
and double-mismatch data, suggesting that nucleotide identity and
RNA:DNA complementarity and binding at the 5′ PAM-distal end is
not required for nuclease activity and that mismatches located at
these positions can be sources of off-targeting.
Although the overall number of functional two-mismatch
sequences was  low, some sequences resulted in a relatively high
percentage of gene editing at the target despite the presence of
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Fig. 3. Gene targeting and relative off-targeting in a phenotypic assay. (A) Functionality of crRNAs containing single-base mismatches at every position of the 20-nt crRNA
spacer  sequence using the Ubi-GFP U2OS–Cas9 EGFP ﬂuorescence assay. (B) A ranked plot of 2-base-mismatched crRNA variants of VCP 2. The 20 highest-signal mismatched
crRNAs are plotted in the main graphic and the full set of 190 crRNAs is shown in the inset. (C) A ranked plot of 2-base-mismatched crRNA variants of PSMD7 1. The 20
highest-signal mismatched crRNAs are plotted in the main graphic and the set of 190 crRNAs is shown in the inset. Untreated sample control (green), perfect match crRNA
control  (red), 2-base-mismatched crRNAs exhibiting a phenotype with robust z-score > 100 (blue), and crRNAs with insigniﬁcant signal (black). (D) Functionality of crRNAs
containing three mismatches to the target site in VCP. Untreated sample control (green), perfect match crRNA control (red) (For interpretation of the references to color in
this  ﬁgure legend, the reader is referred to the web version of this article.).
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Table  1
Signiﬁcantly off-targeting crRNA guide sequences.
Name crRNA guide sequence Avg% Std Dev Robust z-score
VCP 2 (1,2) a g A U C A A C A A U U A A C C G A U U 0.81 0.07 785
VCP 2 (1,6) a C A U C u A C A A U U A A C C G A U U 0.50 0.15 482
VCP  2 (1,7) a C A U C A u C A A U U A A C C G A U U 0.20 0.05 193
VCP  2 (1,9) a C A U C A A C u A U U A A C C G A U U 0.77 0.17 750
VCP  2 (6,7) U C A U C u u C A A U U A A C C G A U U 0.66 0.16 638
VCP  2 (6,9) U C A U C u A C u A U U A A C C G A U U 0.17 0.05 169
VCP  2 (9,10) U C A U C A A C u u U U A A C C G A U U 0.14 0.01 132
PSMD7 1 (1,2) u c C G G G G U G U G U C G C G A U G C 0.92 0.06 896
PSMD7 1 (1,3) u G g G G G G U G U G U C G C G A U G C 0.80 0.04 779
PSMD7 1 (1,4) u G C c G G G U G U G U C G C G A U G C 0.26 0.03 257
PSMD7 1 (1,8) u G C G G G G a G U G U C G C G A U G C 0.69 0.07 676
PSMD7 1 (1,9) u G C G G G G U c U G U C G C G A U G C 0.15 0.02 150
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aPSMD7 1 (1,10) u G C G G G G U G a G 
PSMD7 1 (1,13) u G C G G G G U G U G 
PSMD7 1 (2,5) A c C G c G G U G U G 
wo mismatches. In order to further characterize the functionality
f these mismatched crRNAs, we performed a dose-curve analy-
is of the 3 strongest double-mismatch sequences for the PSMD7 1
nd VCP 2 crRNAs (mismatches at positions 1, 2; 1, 3; and 1, 8 for
SMD7 1 and mismatches at positions 1, 2; 1, 9; and 6, 7 for VCP 2).
esults from the phenotypic assay for both PSMD7 1 and VCP 2
rRNAs indicate that while there is a reduction in editing activity of
rRNAs containing two mismatches, there is a concurrent reduction
n editing efﬁciency of the perfect match crRNA (Fig. 4C and D). This
uggests that a reduction in concentration of crRNA cannot effec-
ively reduce off-targeting without also reducing on-target editing.
he data also show that gene editing efﬁciency begins to plateau
t a concentration of approximately 10 nM crRNA:tracrRNA com-
lex, consistent with Cas9, rather than crRNA or tracrRNA, being
he limiting component for editing.
ig. 4. Characterization of off-targeting crRNAs: T7EI mismatch-detection assay of crRNA
rRNA. (A) VCP 2. (B) PSMD7 1. Dose curve of crRNAs targeting (C) VCP and (D) PSMD7, bot
ssessed using the EGFP phenotypic assay.C G C G A U G C 0.60 0.04 582
g G C G A U G C 0.44 0.10 431
C G C G A U G C 0.16 0.04 159
4. Discussion
Speciﬁcity of all gene editing technologies is a concern for
researchers since genetic background is paramount for exper-
imental interpretation. CRISPR–Cas9 gene editing technology
off-targeting is of particular concern because this technology relies
on sequence binding, and imperfect complementarity between the
crRNA target sequence and genomic DNA can potentially direct
unintended editing.
While the effect of mismatches to target (when generated in an
sgRNA targeting sequence) has been considered previously (Cho
et al., 2014; Fu et al., 2013; Pattanayak et al., 2013; Hsu et al.,
2013), a comprehensive study of the effects of all combinations
of two mismatches between the crRNA and target DNA has not
been published to date. We  used a novel high-throughput approach
s that are either perfectly matched to their target or contain two mismatches in the
h with complete complementarity as well as with the indicated double mismatches,
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nvolving synthesis of synthetic crRNAs along with a sensitive, func-
ional reporter assay that identiﬁes crRNA target sites that result
n functional gene knockout. This assay will only identify crRNA
ites that result in a functional knockout and will not be useful
or the study of crRNA sites that result in indels but do not result
n functional knockout likely due to the editing position in the
ene. Therefore, only crRNA sites that result in functional knock-
ut and phenotype with a large dynamic range were selected for
he systematic evaluation of functional gene editing of all posi-
ional combinations of double mismatches in the context of two
ative crRNA sequences. The main advantage of our approach is
hat the contribution of each position in the targeting 20-mer could
e evaluated on a well-by-well basis without concern for whether
he mismatched sequence occurs endogenously in the genome, and
ithout the additional confounding effects such as variable PAMs,
iffering genomic context of targeted sequence, and so forth for
ach endogenous off-target pairing.
Consistent with previous results, we observed that single mis-
atches are fairly well-tolerated, especially in the 5′ PAM-distal
nd of crRNAs. crRNAs containing mismatches in the seed region,
eﬁned here as nucleotides 11–20 of the crRNA, did not exhibit
ctivity, with two minor exceptions: positions 13 and 19 showed
etectable activity < 10% relative to the perfect match control.
onclusions from the comprehensive examination of two-base
ismatches also agree with published data on selected endogenous
ff-targets. Namely, consecutive two-base mismatches are gener-
lly not active, with the exception of positions 1 and 2. Two-base
ismatches exhibiting function are well-separated (in the non-
eed region) and most often involve one mismatch at the most
istal end from the PAM, indicating that the identity of this base
s dispensable for activity and speciﬁcity of Cas9. Tolerance of mis-
atches distal to the PAM is consistent with the PAM surveillance
echanism and conformational changes required for Cas9 cleavage
hat have been proposed in biochemical studies (Sternberg et al.,
014; Szczelkun et al., 2014).
Surprisingly, the overall number of active two-base-
ismatched sequences was lower than expected based on
rior studies (Fu et al., 2013; Hsu et al., 2013) that found a hit
ate of 6–26% of endogenous 2- and 3-base mismatched off-target
ites (depending on initial targeting sequence) to exhibit fractional
leavage activity. Previous publications concluded that highly
C-rich sequences (60–80%) yield more off-targets containing any
umber of mismatches between one and three. However we  used
equences containing 30% (VCP 2) and 70% GC content (PSMD7 1),
espectively, and found an overall hit rate of only 15/380, or 4%.
ur results most closely agree with the conclusion of Cho et al.
2014), who stated “RGENs cannot efﬁciently cleave chromosomal
NA with mismatches of two or more nucleotides, at least one of
hich occurs in the seed region”. Considering that either on-target
r off-target activity will strictly require a PAM, (thus limiting the
ast number of possible 1-, 2-, and 3-base-mismatched off-targets
o only the subset which occur in the genome adjacent to a PAM)
nd that only a small fraction of these possible sites, in context of
he current study, show activity, our results support the conclusion
hat off-targeting is not as much of an impediment to the use of
RISPR–Cas9 as was initially suggested. Several methods have
ecently emerged that enable proﬁling of genome-wide off-target
leavage by CRISPR–Cas9 (Tsai et al., 2015; Frock et al., 2015;
ang et al., 2015). While GUIDE-Seq may  provide an approach to
etect genome-wide off-target cleavage for single sgRNAs in a low
hroughput manner, our method allows detection of functional
enome editing and serves as a proxy method for off-targeting
hrough the use of numerous, unbiased mismatches to a crRNA
ith similar sensitivity to these published methods but also
n a high-throughput manner with respect to both targets and
ff-targets detected.echnology 211 (2015) 56–65
Bioinformatic approaches have been used to avoid designing
crRNAs that have potential off-target sites in the genome with a
small number of mismatches (1 or possibly 2). However, when
ﬁltering out all crRNAs with any 2- and 3-base-mismatched sites
against the entire human genome, the number of crRNAs remaining
for any given target rapidly decreases. Since crRNA functional-
ity differs, and several crRNAs should be tested per target to
ensure effective gene editing, a solely bioinformatic approach is
not a viable strategy to identify highly speciﬁc crRNAs. In addition,
for creating gene knockins through homology-directed repair, the
location of the CRISPR–Cas9-mediated DSB is even more important
than for knockout. Therefore, understanding the off-target poten-
tial of a given crRNA that may  have one or more mismatches to
potential targets in the genome remains important. Several papers
have proposed modiﬁcations of the standard CRISPR–Cas9 system
to enhance speciﬁcity and reduce off-target cleavage (Ran et al.,
2013; Fu et al., 2014; Tsai et al., 2014). While these techniques
have been shown to increase the overall speciﬁcity of CRISPR–Cas9,
some off-targeting will remain, and in some cases enhanced speci-
ﬁcity using these modiﬁed CRISPR–Cas9 systems may  come at
the expense of decreased on-targeting efﬁciency. In cases where
the mismatched off-target has mismatches only in the PAM-distal
region, off-targets containing mismatches at position 1 are likely
to be prevalent. This information is consistent with a recent publi-
cation (Tsai et al., 2015) and further supports the need to consider
position 1 in crRNA design rules. More target/off-target sets will
need to be tested to predict precise bioinformatic rules for off-
targeting; however, the rapid ability to test many synthetic crRNAs
per gene target and some understanding of mismatch tolerance are
essential to triage designs for highly speciﬁc and functional crRNAs.
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